Skip to main content

Moderna Inc (MRNA) Stock

Moderna Inc Stock Details, Movements and Public Alerts

Stock Details

Moderna Inc (MRNA), a prominent company in the healthcare sector within the biotechnology industry, is based in USA and primarily trades on the NASDAQ.Currently, the stock is trading at $46.03. Over the past 52 weeks, it has ranged between $22.28 and $55.20. This places the current price at 83.4% of its 52-week high and 106.6% above its 52-week low. Recent trading volume was recorded at 1,383. The 14-day Relative Strength Index (RSI) stands at 65.87, suggesting neutral conditions. The stock is currently trading above its 50-day moving average of $32.90 by 39.91%. Similarly, it is above its 200-day moving average of $28.50 by 61.51%. The MACD histogram is 0.29, indicating bullish momentum (MACD Line: 4.44, Signal Line: 4.15). The International Securities Identification Number (ISIN) for this stock is US60770K1079. There are currently 3 active alerts set for MRNA by users.

52-Week Range

$55.20 - $22.28

-16.61% from high · +106.60% from low

Avg Daily Volume

14,640,079

20-day average

100-day avg: 11,746,793

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Forward P/E

32.47

PEG Ratio

0.00

Potentially undervalued

Price to Book

1.90

EV/EBITDA

4.64

EPS (TTM)

-$8.06

Price to Sales

7.93

Beta

1.17

Similar volatility to market

Q:How is MRNA valued relative to its earnings and growth?
Valuation data is not available for this stock.
Q:What is MRNA's risk profile compared to the market?
With a beta of 1.17, Moderna Inc is roughly as volatile as the market, moving in line with broad market trends. This moderate beta suggests the stock offers market-level returns without excessive volatility. The price-to-book ratio of 1.90 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

-139.60%

Operating Margin

-25.60%

EBITDA

$-3,255,000,064

Return on Equity

-29.30%

Return on Assets

-15.50%

Revenue Growth (YoY)

-45.40%

Earnings Growth (YoY)

-85.10%

Q:How profitable and efficient is MRNA's business model?
Moderna Inc achieves a profit margin of -139.60%, meaning it retains $-139.60 from every $100 in revenue after all expenses. This relatively low margin suggests the company operates in a competitive environment or high-cost industry where profitability is challenging. The operating margin of -25.60% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at -29.30% and ROA at -15.50%, the company achieves moderate returns on invested capital.
Q:What are MRNA's recent growth trends?
Moderna Inc's revenue declined by 45.40% year-over-year, indicating challenges in maintaining sales momentum. This contraction may reflect market headwinds, competitive pressures, or strategic transitions. Earnings decreased by 85.10% year-over-year, reflecting the bottom-line impact of business performance. These growth metrics should be evaluated against BIOTECHNOLOGY industry averages for proper context.

Company Size & Market

Market Cap

$17.7B

Revenue (TTM)

$2.23B

Revenue/Share (TTM)

$5.76

Shares Outstanding

390.73M

Book Value/Share

$23.86

Asset Type

Common Stock

Q:What is MRNA's market capitalization and position?
Moderna Inc has a market capitalization of $17.7B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 390.73M shares outstanding, the company's ownership is relatively concentrated. As a participant in the BIOTECHNOLOGY industry, it competes with other firms in this sector.
Q:How does MRNA's price compare to its book value?
Moderna Inc's book value per share is $23.86, while the current stock price is $46.03, resulting in a price-to-book (P/B) ratio of 1.93. This reasonable premium to book value suggests the market values the company's earnings power and intangible assets appropriately. Most profitable companies trade between 1-3x book value. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$37.70

18.10% downside potential

Analyst Recommendations

Strong Buy

2

Buy

3

Hold

16

Sell

1

Strong Sell

2

Q:How reliable are analyst predictions for MRNA?
24 analysts cover MRNA with 21% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The bearish sentiment could create opportunity if analysts are wrong. The consensus target of $37.70 implies -18.1% downside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on MRNA?
Current analyst recommendations:2 Strong Buy, 3 Buy, 16 Hold, 1 Sell, 2 Strong Sell. The neutral stance suggests uncertainty or fair valuation at current levels.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Jan 30, 2026, 02:03 AM

Technical Indicators

RSI (14-day)

65.87

Neutral

50-Day Moving Average

$32.90

39.91% above MA-50

200-Day Moving Average

$28.50

61.51% above MA-200

MACD Line

4.44

MACD Signal

4.15

MACD Histogram

0.29

Bullish

Q:What does MRNA's RSI value tell investors?
The RSI (Relative Strength Index) for MRNA is currently 65.87, indicating the stock is showing bullish momentum (60-70 range). The stock has positive momentum without being extremely overbought. This zone often occurs during healthy uptrends where buyers remain in control. Combined with the price being above the 50-day moving average, this confirms bullish conditions.
Q:How should traders interpret MRNA's MACD and moving average crossovers?
MACD analysis shows the MACD line at 4.44 above the signal line at 4.15, with histogram at 0.29. This bullish crossover suggests upward momentum is building. The 50-day MA ($32.90) is above the 200-day MA ($28.50), forming a golden cross pattern that typically signals a long-term uptrend. Price is currently above both MAs, confirming strength.

Indicators last updated: Jan 30, 2026, 12:57 AM

Active Alerts

Alert Condition
RSI Threshold Cross
Threshold
70
Created
Jan 26, 2026, 04:01 PM
Alert Condition
Price decreases by
Threshold
8%
Created
Jan 9, 2026, 04:03 PM
Alert Condition
MA Breakout (Bearish)
Threshold
50 days
Created
Jan 1, 2026, 04:01 PM

Stay Ahead of the Market with Moderna Inc Alerts

Set up price alerts for Moderna Inc and get notified instantly when the price hits your target. Never miss an important price movement again.